Blood cancers, Chronic leukaemia, Chronic lymphocytic leukaemia (CLL), Leukaemia
Results
Phase 2
This trial used alemtuzumab (Mabcampath) to reduce the small number of leukaemia cells left in the blood after treatment for chronic lymphocytic leukaemia.
Recruitment start: 13 November 2006
Recruitment end: 31 January 2010
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Peter Hillmen
Leeds Institute of Clinical Trials Research, University of Leeds
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
Genzyme Therapeutics
NIHR Clinical Research Network: Cancer
This is Cancer Research UK trial number CRUKE/06/038.
Last reviewed: 9 July 2017
CRUK internal database number: 826
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
